--- title: "Viemed Healthcare | 8-K: FY2026 Q2 Revenue Beats Estimate at USD 78.1 M" type: "News" locale: "en" url: "https://longbridge.com/en/news/294738916.md" datetime: "2026-08-03T21:04:16.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/294738916.md) - [en](https://longbridge.com/en/news/294738916.md) - [zh-HK](https://longbridge.com/zh-HK/news/294738916.md) --- # Viemed Healthcare | 8-K: FY2026 Q2 Revenue Beats Estimate at USD 78.1 M Revenue: As of FY2026 Q2, the actual value is USD 78.1 M, beating the estimate of USD 78 M. EPS: As of FY2026 Q2, the actual value is USD 0.07, missing the estimate of USD 0.12. EBIT: As of FY2026 Q2, the actual value is USD 4.709 M. ### Financial Highlights for Three Months Ended June 30, 2026 (Q2 2026) #### Revenue Viemed Healthcare, Inc. reported record net revenues of $78.1 million, an increase of $15.0 million, or 23.9%, compared with the prior-year quarter, and approximately 3.6% sequentially. Total revenues for the quarter were $78,097 thousand. ##### Segment Revenue (Q2 2026, in thousands of U.S. Dollars) - **Rental Revenue** - Ventilators, non-invasive & invasive: $36,411 - Other home medical equipment rentals: $16,408 - **Sales & Service Revenue** - Equipment and supply sales: $18,971 - Service revenues: $6,307 #### Net Income Net income attributable to Viemed Healthcare, Inc. totaled $2.8 million, or $0.07 per diluted share. Net Income attributable to Viemed Healthcare, Inc. for Q2 2026 was $2,764 thousand. #### Gross Profit Gross profit for the quarter was $45,048 thousand, compared to $36,731 thousand for the same period in 2025. The gross profit margin was 58%. #### Income from Operations Income from operations was $4,461 thousand, down from $5,095 thousand in the prior-year quarter. #### Adjusted EBITDA Adjusted EBITDA for the quarter totaled $13.7 million, a 4.0% decrease as compared to the quarter ended June 30, 2025. Adjusted EBITDA totaled $13,715 thousand, representing a 4% decrease year-over-year. #### Cash Flow Net cash provided by operating activities totaled $15.9 million for the quarter and $60.8 million for the trailing twelve months ended June 30, 2026. For the six months ended June 30, 2026, net cash provided by operating activities was $23,973 thousand, up from $15,108 thousand in the same period of 2025. Free cash flow totaled $8.6 million for the quarter and $34.4 million for the trailing twelve months ended June 30, 2026. #### Balance Sheet (as of June 30, 2026) Viemed Healthcare, Inc. maintained a cash balance of $10.7 million. Cash and Cash Equivalents were $10,680 thousand. The company had an overall working capital balance of $6.1 million. Working Capital stood at $6,072 thousand. Long-term debt totaled $6.4 million. Long Term Debt was $6,374 thousand. The company had $46 million in unfunded commitments available under its existing credit facilities. #### Share Repurchase During the second quarter of 2026, Viemed Healthcare, Inc. repurchased and cancelled 530,802 common shares under its share repurchase program at a cost of $5.1 million (excluding taxes), representing an average buyback price of $9.65 per share. #### Capital Expenditures and Allocation Net capital expenditures totaled $7.3 million, or 9.3% of revenue, for Q2 2026. First-half net capital expenditures were $12.8 million, or 8.3% of revenue. The company reduced debt through $2.2 million of term loan repayments. ### Operational Metrics for Three Months Ended June 30, 2026 (Q2 2026) #### Ventilator Patients Viemed Healthcare, Inc. ended the second quarter of 2026 with a record 12,635 ventilator patients, an increase of 4.0% over June 30, 2025, and a 4.5% sequential increase from March 31, 2026. This represents the highest census in company history. #### PAP Therapy Patient Count The company increased its PAP therapy patient count to 37,825, an increase of 44.0% over June 30, 2025, and a 5.3% sequential increase from March 31, 2026. #### Sleep Resupply Patient Count The company’s sleep resupply patient count was 37,035, up 46.7% year over year and 10.0% sequentially. ### Full Year 2026 Guidance Viemed Healthcare, Inc. raised the low end and narrowed its full-year net revenue guidance to a range of $314 million to $320 million, compared with the previous range of $312 million to $320 million. Adjusted EBITDA is now expected to range from $64 million to $68 million, revised from the previous range of $65 million to $69 million. Net capital expenditures are now expected to range from 8.5% to 10.0% of net revenue, a decrease from the previous range of 9.0% to 10.5%, reflecting a growing contribution from less capital-intensive product and service revenue. ### Related Stocks - [VMD.US](https://longbridge.com/en/quote/VMD.US.md) ## Related News & Research - [Viemed Healthcare reports mixed Q4 results; introduces FY26 outlook](https://longbridge.com/en/news/277881209.md) - [Viemed Healthcare (VMD) to Release Quarterly Earnings on Tuesday](https://longbridge.com/en/news/284420929.md) - [VMD Sciences Expands Veterinary Pharmaceutical Supply Solutions to Address Drug Shortages and Emerging Disease Threats in the United States](https://longbridge.com/en/news/287125444.md) - [Stonegate Capital Partners Updates Coverage on Viemed Healthcare, Inc. (VMD) 1Q26 | VMD Stock News](https://longbridge.com/en/news/286118741.md) - [Viemed Healthcare Q4 Earnings Call Highlights](https://longbridge.com/en/news/278028978.md)